On October 24, 2024, the Center for Drug Evaluation of the National Medical Products Administration indicated that the influenza virus split vaccine marketing application from Chongqing Zhifei Biological Products Co., Ltd. (SHE: 300122)’s wholly-owned subsidiary, Zhifei Longkoma, has been accepted, with the acceptance number CXSS2400114.
Currently, Chongqing Zhifei Biological has established nine major technical research platforms, including polysaccharide and conjugate technology platforms, recombinant technology platforms, inactivated technology platforms, and multi-component multi-valent technology platforms, covering a wide range of vaccine development pathways. Around these nine technical platforms, the company has formed a clear and well-structured product matrix, including meningococcal vaccine matrix, pneumonia vaccine matrix, intestinal vaccine matrix, and adult vaccine matrix.
The influenza virus split vaccine applied for marketing by the company this time is a product in its adult vaccine matrix. In terms of influenza vaccines, Chongqing Zhifei Biological’s related products also include quadrivalent influenza virus split vaccine and quadrivalent influenza virus split vaccine (ZFA02 adjuvant).
According to the biological product batch release situation disclosed by the China Institute of Biological Products, in the first half of 2024, domestic influenza vaccines were released in 181 batches. Among them, influenza split vaccines accounted for the majority, with 173 batches released, an increase of 8.6 times compared to the same period last year.- Flcube.com
